Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEDAPAP vs SURITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.
SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.
Management of moderate to moderately severe pain where an opioid analgesic is required
Induction of anesthesia,Maintenance of anesthesia as part of balanced anesthesia,Adjunct to regional anesthesia,Control of convulsive states (off-label)
1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.
Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In patients with creatinine clearance <30 m L/min, the half-life may be prolonged to 10-15 hours, requiring dose adjustment.
Terminal elimination half-life 2-8 hours (mean 4.5 h) in adults; prolonged in hepatic impairment.
Hydrocodone is metabolized primarily via CYP3A4 and CYP2D6 to hydromorphone and other metabolites. Acetaminophen is metabolized primarily via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Primarily hepatic metabolism via microsomal enzyme oxidation (CYP2B6, CYP3A4) to inactive metabolites; minor renal excretion.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose. Hepatic metabolism to inactive metabolites, followed by biliary and fecal elimination, accounts for the remaining 30-40%. Less than 5% is excreted unchanged in feces.
Primarily renal excretion of metabolites; <1% unchanged. Minor biliary/fecal elimination.
Approximately 92-95% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
~70% bound to albumin.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. Higher Vd is observed in obesity (up to 1.5 L/kg).
1.5-2.5 L/kg; indicates extensive tissue distribution.
Oral: 75-85% due to first-pass metabolism. Intramuscular: 90-100%. Intravenous: 100%.
IM: ~90%.
GFR 30-50 m L/min: Use with caution, maximum 4 tablets per day. GFR <30 m L/min: Contraindicated due to butalbital accumulation.
No specific GFR-based adjustments; metabolized primarily in liver. Caution in severe renal impairment due to potential accumulation of inactive metabolites.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%, maximum 3 tablets per day. Child-Pugh C: Contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate to effect. Child-Pugh C: Contraindicated or use with extreme caution with reduced doses (e.g., 25-50% of normal).
Not recommended for patients under 12 years of age.
Induction: 3-6 mg/kg IV. Maintenance: 1-2 mg/kg IV as needed. Use with caution; not recommended for neonates.
Initiate at lowest effective dose (1 tablet every 6 hours); monitor for excessive sedation and cognitive impairment.
Reduce dose by 30-50% due to decreased clearance and increased sensitivity. Administer slowly and titrate to effect.
Addiction, Abuse, and Misuse: SEDAPAP exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation and dose titration. Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can cause fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. Cytochrome P450 3A4 Interaction: Concomitant use with CYP3A4 inhibitors may increase hydrocodone levels and prolong adverse effects. Concomitant use with CYP3A4 inducers may decrease efficacy. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
WARNING: RESPIRATORY DEPRESSION AND CARDIAC ARREST. SURITAL may cause severe respiratory depression or apnea, especially with rapid administration. Resuscitative equipment and personnel trained in airway management must be immediately available. Avoid intra-arterial injection due to risk of arteriospasm, thrombosis, and gangrene.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity (due to acetaminophen); opioid-induced hyperalgesia; withdrawal; risks of use in patients with head injuries, impaired consciousness, or increased intracranial pressure; use in patients with gastrointestinal conditions including paralytic ileus; use in patients with severe renal or hepatic impairment; use in elderly, cachectic, or debilitated patients; use in patients with pulmonary disease; use in patients with biliary tract disease; use in patients with acute pancreatitis; use in patients with CNS depression; use in patients with toxic psychosis; use in patients with known or suspected surgical abdomen; use in patients with urinary retention; use in patients with prostatic hypertrophy; use in patients with urethral stricture; use in patients with hypothyroidism; use in patients with Addison's disease; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with seizures or seizure disorders; use in patients with substance abuse history; driving and operating machinery; use in pregnancy; use in lactation.
Monitor respiratory and cardiac function continuously; use with caution in patients with respiratory compromise, hypotension, shock, or hepatic/renal impairment; may cause laryngospasm, bronchospasm, or hypotension; avoid extravasation; use with caution in porphyria.
Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Absolute: Known hypersensitivity to barbiturates, acute intermittent porphyria, severe respiratory insufficiency, status asthmaticus, and conditions where general anesthesia is contraindicated.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. High-fat meals may delay absorption but not clinically significant. No specific food restrictions.
No specific food interactions reported for Surital (thiamylal). However, patients should avoid consuming grapefruit or grapefruit juice for 24 hours before and after administration, as it may theoretically inhibit cytochrome P450 metabolism, although significant interactions are not well-documented.
First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities, cardiac defects, developmental delay), neonatal hemorrhage due to vitamin K deficiency (valproate), and withdrawal syndrome. Acetaminophen carries minimal risk.
Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited human data. Second/third trimester: Increased risk of preterm labor, fetal bradycardia, neonatal respiratory depression, and withdrawal syndrome. Avoid use during pregnancy unless clearly needed.
Both valproate and acetaminophen are excreted into breast milk. Valproate M/P ratio approximately 0.05-0.1; infant serum levels low but potential for hepatotoxicity and thrombocytopenia. Acetaminophen M/P ratio ~1.0, considered safe in therapeutic doses. Caution advised with valproate; monitor infant for jaundice, bruising, and sedation.
Excretion into breast milk is unknown; M/P ratio not established. Due to high lipid solubility, potential for significant transfer. Consider risks of neonatal CNS depression. Use with caution; monitor infant for sedation, poor feeding, and respiratory depression. Alternative agents preferred.
Valproate: Dose may need reduction due to increased clearance (plasma levels decrease 30-50% in late pregnancy); monitor serum levels and adjust to maintain therapeutic concentration. Acetaminophen: No dose adjustment required in pregnancy; standard dosing recommended.
Increased volume of distribution and hepatic metabolism in pregnancy may require higher induction doses and more frequent maintenance doses. However, due to fetal risks, avoid use in pregnancy unless absolutely necessary. If used, start at lower range (e.g., 3-4 mg/kg IV induction) and titrate to effect. No established dose adjustment guidelines; individualize based on clinical response and close monitoring.
SEDAPAP is a combination product containing an opioid (codeine or hydrocodone) and acetaminophen. Avoid exceeding 3 grams/day of acetaminophen to prevent hepatotoxicity. Monitor respiratory depression, especially in opioid-naive patients and those with sleep apnea. Use with caution in hepatic impairment, ethanol use disorder, and in patients on other CNS depressants. Administer with food to reduce GI upset.
Surital (thiamylal) is an ultra-short-acting barbiturate used for induction of anesthesia. Due to its high lipid solubility, onset of action is rapid (<30 seconds). It is contraindicated in porphyria and should be used with caution in patients with hepatic impairment, as it is metabolized in the liver. Extravasation causes tissue necrosis; use a large vein for IV administration. Respiratory depression and laryngospasm are common during induction. Surital has no analgesic properties and may cause myocardial depression at high doses. For short procedures, it provides rapid awakening but with potential residual sedation.
Do not exceed recommended dose; too much acetaminophen can cause liver damage.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food or milk if stomach upset occurs.,Report any difficulty breathing, severe constipation, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.,Do not stop suddenly after prolonged use to avoid withdrawal symptoms.
This medication is used to put you to sleep before surgery or certain procedures.,You may feel dizzy or drowsy for several hours after receiving this drug; do not drive or operate machinery for at least 24 hours.,Avoid alcohol for at least 24 hours after receiving this medication as it can increase side effects.,Inform your healthcare provider if you have a history of porphyria, liver disease, or respiratory problems.,Do not breastfeed for at least 24 hours after administration without consulting your doctor.,Notify your doctor immediately if you experience severe pain, redness, or swelling at the injection site.,You may experience temporary confusion or memory loss after waking up; this is normal and should resolve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SEDAPAP vs SURITAL, answered by our medical review team.
SEDAPAP is a Barbiturate Combination Analgesic that works by SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.. SURITAL is a Barbiturate Anesthetic that works by SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SEDAPAP and SURITAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SEDAPAP is: 1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.. The standard adult dose of SURITAL is: Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SEDAPAP and SURITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SEDAPAP is classified as Category C. First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities. SURITAL is classified as Category C. Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited hu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.